{"id":"depo-testosterone","rwe":[{"pmid":"41503895","year":"2026","title":"Myocardial Infarction, Pulmonary Embolism, and Deep Vein Thrombosis Following Testosterone Cypionate Use: A Pharmacovigilance Study.","finding":"","journal":"Current drug safety","studyType":"Clinical Study"},{"pmid":"41208903","year":"2025","title":"Accuracy of Anthropometric Equations in Estimating Body Fat Percentage in Transgender Men Undergoing Gender-Affirming Hormone Therapy.","finding":"","journal":"International journal of exercise science","studyType":"Clinical Study"},{"pmid":"41150624","year":"2025","title":"Determinants of Pubertal Growth Spurt in Constitutional Delay of Growth and Puberty in Boys Treated With Testosterone.","finding":"","journal":"Rhode Island medical journal (2013)","studyType":"Clinical Study"},{"pmid":"41052128","year":"2025","title":"Effect of 100 mg of testosterone cypionate in trans men with erythrocytosis: a randomized controlled pilot study.","finding":"","journal":"The journal of sexual medicine","studyType":"Clinical Study"},{"pmid":"40895441","year":"2025","title":"Cross-sex hormone therapy in rats induces sex-specific adaptations of renal function and sodium transporters expression.","finding":"","journal":"Frontiers in physiology","studyType":"Clinical Study"}],"_fda":{"id":"110449a6-1353-41e1-a41e-cb4cb4f0a5ae","set_id":"08f88e0e-d9a4-4a03-9286-46d9bf9a363e","openfda":{"unii":["M0XW1UBI14"],"route":["INTRAMUSCULAR"],"rxcui":["2047882"],"spl_id":["110449a6-1353-41e1-a41e-cb4cb4f0a5ae"],"brand_name":["Testosterone Cypionate"],"spl_set_id":["08f88e0e-d9a4-4a03-9286-46d9bf9a363e"],"package_ndc":["0517-1830-01"],"product_ndc":["0517-1830"],"generic_name":["TESTOSTERONE CYPIONATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["TESTOSTERONE CYPIONATE"],"manufacturer_name":["American Regent, Inc."],"application_number":["ANDA207742"],"is_original_packager":[true]},"version":"14","warnings":["WARNINGS Hypercalcemia may occur in immobilized patients. If this occurs, the drug should be discontinued. Prolonged use of high doses of androgens (principally the 17-α alkyl-androgens) has been associated with development of hepatic adenomas, hepatocellular carcinoma, and peliosis hepatis —all potentially life-threatening complications. Geriatric patients treated with androgens may be at an increased risk of developing prostatic hypertrophy and prostatic carcinoma although conclusive evidence to support this concept is lacking. There have been postmarketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products, such as testosterone cypionate. Evaluate patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE. If a venous thromboembolic event is suspected, discontinue treatment with testosterone cypionate and initiate appropriate workup and management. Long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-­fatal stroke, and cardiovascular death, with the use of testosterone compared to non-use. Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy in men. Patients should be informed of this possible risk when deciding whether to use or to continue to use testosterone cypionate injection. Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions (see DRUG ABUSE AND DEPENDENCE ). If testosterone abuse is suspected, check serum testosterone concentrations to ensure they are within therapeutic range. However, testosterone levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives. Counsel patients concerning the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids. Conversely, consider the possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events. Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal or hepatic disease. Gynecomastia may develop and occasionally persists in patients being treated for hypogonadism. The preservative benzyl alcohol has been associated with serious adverse events, including the “gasping syndrome”, and death in pediatric patients. Although normal therapeutic doses of this product ordinarily deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the “gasping syndrome”, the minimum amount of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol toxicity depends on the quantity administered and the liver and kidneys' capacity to detoxify the chemical. Premature and low-birth weight infants may be more likely to develop toxicity. Androgen therapy should be used cautiously in healthy males with delayed puberty. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every 6 months. In children, androgen treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height. This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose."],"pregnancy":["Pregnancy Teratogenic Effects The use of testosterone in women who are pregnant is contraindicated. Testosterone is teratogenic and may cause fetal harm. Testosterone is known to cause virilization of the female fetus when administrated to pregnant women. Benzyl alcohol can cross the placenta. See WARNINGS ."],"overdosage":["OVERDOSAGE There have been no reports of acute overdosage with the androgens."],"description":["DESCRIPTION Testosterone Cypionate Injection, USP, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1-oxopropoxy)-, (17β)-. Its molecular formula is C 27 H 40 O 3 , and the molecular weight 412.61. The structural formula is represented below: Testosterone Cypionate Injection, USP is available as 200 mg/mL testosterone cypionate. Each mL of the solution contains Testosterone Cypionate, 200 mg; Benzyl Benzoate, 0.2 mL; Cottonseed Oil, 560 mg; Benzyl Alcohol (as preservative), 9.45 mg. Structural Formula"],"precautions":["PRECAUTIONS General Patients with benign prostatic hypertrophy may develop acute urethral obstruction. Priapism or excessive sexual stimulation may develop. Oligospermia may occur after prolonged administration or excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized. Testosterone cypionate should not be used interchangeably with testosterone propionate because of differences in duration of action. Testosterone cypionate is not for intravenous use. Information for Patients Patients should be instructed to report any of the following: nausea, vomiting, changes in skin color, ankle swelling, too frequent or persistent erections of the penis. Laboratory Tests Hemoglobin and hematocrit levels (to detect polycythemia) should be checked periodically in patients receiving long-term androgen administration. Serum cholesterol may increase during androgen therapy. Drug Interactions Androgens may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia. Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, insulin requirements. Drug/Laboratory Test Interferences Androgens may decrease levels of thyroxine-binding globulin, resulting in decreased total T 4 serum levels and increased resin uptake of T 3 and T 4 . Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. Carcinogenesis Animal data Testosterone has been tested by subcutaneous injection and implantation in mice and rats. The implant induced cervical-uterine tumors in mice, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats. Human data There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with androgens in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases. Geriatric patients treated with androgens may be at an increased risk of developing prostatic hypertrophy and prostatic carcinoma although conclusive evidence to support this concept is lacking. Pregnancy Teratogenic Effects The use of testosterone in women who are pregnant is contraindicated. Testosterone is teratogenic and may cause fetal harm. Testosterone is known to cause virilization of the female fetus when administrated to pregnant women. Benzyl alcohol can cross the placenta. See WARNINGS . Nursing Mothers Testosterone cypionate injection is not recommended for use in nursing mothers. Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 years have not been established."],"how_supplied":["HOW SUPPLIED Testosterone Cypionate Injection, USP, 200 mg/mL is available as follows: 1 mL Vials NDC 0517-1830-01 Individually Packaged 10 mL Vials NDC 0517-1831-01 IndividuallyPackaged Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light."],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 years have not been established."],"effective_time":"20190617","nursing_mothers":["Nursing Mothers Testosterone cypionate injection is not recommended for use in nursing mothers."],"laboratory_tests":["Laboratory Tests Hemoglobin and hematocrit levels (to detect polycythemia) should be checked periodically in patients receiving long-term androgen administration. Serum cholesterol may increase during androgen therapy."],"pharmacokinetics":["Pharmacokinetics Testosterone esters are less polar than free testosterone. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase; thus, testosterone cypionate can be given at intervals of two to four weeks. Testosterone in plasma is 98 percent bound to a specific testosterone-estradiol binding globulin, and about 2 percent is free. Generally, the amount of this sex-hormone binding globulin in the plasma will determine the distribution of testosterone between free and bound forms, and the free testosterone concentration will determine its half-life. About 90 percent of a dose of testosterone is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6 percent of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver. Testosterone is metabolized to various 17-keto steroids through two different pathways. The half-life of testosterone cypionate when injected intramuscularly is approximately eight days. In many tissues the activity of testosterone appears to depend on reduction to dihydrotestosterone, which binds to cytosol receptor proteins. The steroid-receptor complex is transported to the nucleus where it initiates transcription events and cellular changes related to androgen action."],"adverse_reactions":["ADVERSE REACTIONS The following adverse reactions in the male have occurred with some androgens: Endocrine and urogenital: Gynecomastia and excessive frequency and duration of penile erections. Oligospermia may occur at high dosages. Skin and appendages: Hirsutism, male pattern of baldness, seborrhea, and acne. Cardiovascular disorders: myocardial infarction, stroke. Fluid and electrolyte disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates. Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests, rarely hepatocellular neoplasms and peliosis hepatis (see WARNINGS ). Hematologic: Suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia. Nervous system: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia. Allergic: Hypersensitivity, including skin manifestations and anaphylactoid reactions. Vascular disorders: Venous thromboembolism Special senses: Rare cases of central serous chorioretinopathy (CSCR). Miscellaneous: Inflammation and pain at the site of intramuscular injection. To report SUSPECTED ADVERSE REACTIONS, contact American Regent, Inc. at 1-800-734-9236 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ."],"contraindications":["CONTRAINDICATIONS 1. Known hypersensitivity to the drug 2. Males with carcinoma of the breast 3. Males with known or suspected carcinoma of the prostate gland 4. Women who are pregnant (see PRECAUTIONS , Pregnancy ) 5. Patients with serious cardiac, hepatic or renal disease (see WARNINGS )"],"drug_interactions":["Drug Interactions Androgens may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia. Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, insulin requirements."],"general_precautions":["General Patients with benign prostatic hypertrophy may develop acute urethral obstruction. Priapism or excessive sexual stimulation may develop. Oligospermia may occur after prolonged administration or excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized. Testosterone cypionate should not be used interchangeably with testosterone propionate because of differences in duration of action. Testosterone cypionate is not for intravenous use."],"teratogenic_effects":["Teratogenic Effects The use of testosterone in women who are pregnant is contraindicated. Testosterone is teratogenic and may cause fetal harm. Testosterone is known to cause virilization of the female fetus when administrated to pregnant women. Benzyl alcohol can cross the placenta. See WARNINGS ."],"controlled_substance":["Controlled Substance Testosterone cypionate injection contains testosterone, a Schedule III controlled substance in the Controlled Substances Act. Abuse Drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. Abuse and misuse of testosterone are seen in male and female adults and adolescents. Testosterone, often in combination with other anabolic androgenic steroids (AAS), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. There have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. Abuse-Related Adverse Reactions Serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility and aggression. The following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility. The following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities. The following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty. Because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Dependence Behaviors Associated with Addiction Continued abuse of testosterone and other anabolic steroids, leading to addiction is characterized by the following behaviors: Taking greater dosages than prescribed Continued drug use despite medical and social problems due to drug use Spending significant time to obtain the drug when supplies of the drug are interrupted Giving a higher priority to drug use than other obligations Having difficulty in discontinuing the drug despite desires and attempts to do so Experiencing withdrawal symptoms upon abrupt discontinuation of use Physical dependence is characterized by withdrawal symptoms after abrupt drug discontinuation or a significant dose reduction of a drug. Individuals taking supratherapeutic doses of testosterone may experience withdrawal symptoms lasting for weeks or months which include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido and hypogonadotropic hypogonadism. Drug dependence in individuals using approved doses of testosterone for approved indications has not been documented."],"storage_and_handling":["Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Endogenous androgens are responsible for normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include growth and maturation of the prostate, seminal vesicles, penis, and scrotum; development of male hair distribution, such as beard, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body musculature and fat distribution. Drugs in this class also cause retention of nitrogen, sodium, potassium, and phosphorous, and decreased urinary excretion of calcium. Androgens have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein. Androgens are responsible for the growth spurt of adolescence and for eventual termination of linear growth, brought about by fusion of the epiphyseal growth centers. In children, exogenous androgens accelerate linear growth rates, but may cause disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of the growth process. Androgens have been reported to stimulate production of red blood cells by enhancing production of erythropoietic stimulation factor. During exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH). There is a lack of substantial evidence that androgens are effective in fractures, surgery, convalescence, and functional uterine bleeding. Pharmacokinetics Testosterone esters are less polar than free testosterone. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase; thus, testosterone cypionate can be given at intervals of two to four weeks. Testosterone in plasma is 98 percent bound to a specific testosterone-estradiol binding globulin, and about 2 percent is free. Generally, the amount of this sex-hormone binding globulin in the plasma will determine the distribution of testosterone between free and bound forms, and the free testosterone concentration will determine its half-life. About 90 percent of a dose of testosterone is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6 percent of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver. Testosterone is metabolized to various 17-keto steroids through two different pathways. The half-life of testosterone cypionate when injected intramuscularly is approximately eight days. In many tissues the activity of testosterone appears to depend on reduction to dihydrotestosterone, which binds to cytosol receptor proteins. The steroid-receptor complex is transported to the nucleus where it initiates transcription events and cellular changes related to androgen action."],"indications_and_usage":["INDICATIONS AND USAGE Testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate injection in men with “age­-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established."],"information_for_patients":["Information for Patients Patients should be instructed to report any of the following: nausea, vomiting, changes in skin color, ankle swelling, too frequent or persistent erections of the penis."],"spl_unclassified_section":["AMERICAN REGENT, INC. SHIRLEY, NY 11967 June 2019 RQ1065-A"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Prior to initiating testosterone cypionate injection, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range. Testosterone cypionate injection is for intramuscular use only. It should not be given intravenously. Intramuscular injections should be given deep in the gluteal muscle. The suggested dosage for testosterone cypionate injection varies depending on the age, sex, and diagnosis of the individual patient. Dosage is adjusted according to the patient's response and the appearance of adverse reactions. Various dosage regimens have been used to induce pubertal changes in hypogonadal males; some experts have advocated lower dosages initially, gradually increasing the dose as puberty progresses, with or without a decrease to maintenance levels. Other experts emphasize that higher dosages are needed to induce pubertal changes and lower dosages can be used for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose. For replacement in the hypogonadal male, 50 to 400 mg should be administered every two to four weeks. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warming and shaking the vial should redissolve any crystals that may have formed during storage at temperatures lower than recommended."],"drug_abuse_and_dependence":["DRUG ABUSE AND DEPENDENCE Controlled Substance Testosterone cypionate injection contains testosterone, a Schedule III controlled substance in the Controlled Substances Act. Abuse Drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. Abuse and misuse of testosterone are seen in male and female adults and adolescents. Testosterone, often in combination with other anabolic androgenic steroids (AAS), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. There have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. Abuse-Related Adverse Reactions Serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility and aggression. The following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility. The following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities. The following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty. Because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Dependence Behaviors Associated with Addiction Continued abuse of testosterone and other anabolic steroids, leading to addiction is characterized by the following behaviors: Taking greater dosages than prescribed Continued drug use despite medical and social problems due to drug use Spending significant time to obtain the drug when supplies of the drug are interrupted Giving a higher priority to drug use than other obligations Having difficulty in discontinuing the drug despite desires and attempts to do so Experiencing withdrawal symptoms upon abrupt discontinuation of use Physical dependence is characterized by withdrawal symptoms after abrupt drug discontinuation or a significant dose reduction of a drug. Individuals taking supratherapeutic doses of testosterone may experience withdrawal symptoms lasting for weeks or months which include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido and hypogonadotropic hypogonadism. Drug dependence in individuals using approved doses of testosterone for approved indications has not been documented."],"spl_product_data_elements":["Testosterone Cypionate Testosterone Cypionate TESTOSTERONE CYPIONATE TESTOSTERONE BENZYL BENZOATE BENZYL ALCOHOL COTTONSEED OIL"],"package_label_principal_display_panel":["PRIMARY DISPLAY PANEL - Container Label - 1 mL NDC 0517-1830-01 Testosterone Cypionate CIII Injection, USP 200 mg/1 mL For Intramuscular Use Only Rx Only AMERICAN REGENT, INC. SHIRLEY, NY 11967 1 mL Container Label","PRIMARY DISPLAY PANEL - Carton Labeling - 1 mL NDC 0517-1830-01 Testosterone Cypionate CIII Injection, USP 200 mg/mL For Intramuscular Use Only One 1 mL Single-Dose Vial Rx Only AMERICAN REGENT, INC. SHIRLEY, NY 11967 Carton Labeling - 1 mL","Serialization Label (1 mL) Serialization Label (1 mL)"],"drug_and_or_laboratory_test_interactions":["Drug/Laboratory Test Interferences Androgens may decrease levels of thyroxine-binding globulin, resulting in decreased total T 4 serum levels and increased resin uptake of T 3 and T 4 . Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis Animal data Testosterone has been tested by subcutaneous injection and implantation in mice and rats. The implant induced cervical-uterine tumors in mice, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats. Human data There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with androgens in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases. Geriatric patients treated with androgens may be at an increased risk of developing prostatic hypertrophy and prostatic carcinoma although conclusive evidence to support this concept is lacking."]},"tags":[{"label":"Androgen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Androgen receptor","category":"target"},{"label":"AR","category":"gene"},{"label":"Intramuscular","category":"route"},{"label":"Injection","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Deficiency of testosterone biosynthesis","category":"indication"},{"label":"Delayed puberty","category":"indication"},{"label":"Hormone receptor positive malignant neoplasm of breast","category":"indication"},{"label":"Klinefelter's syndrome, XXY","category":"indication"},{"label":"LHRH Deficiency","category":"indication"},{"label":"Male hypogonadism","category":"indication"},{"label":"Azurity","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Androgens","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"MYOCARDIAL INFARCTION","source":"FDA FAERS","actionTaken":"947 reports"},{"date":"","signal":"CEREBROVASCULAR ACCIDENT","source":"FDA FAERS","actionTaken":"682 reports"},{"date":"","signal":"DEEP VEIN THROMBOSIS","source":"FDA FAERS","actionTaken":"619 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"579 reports"},{"date":"","signal":"PULMONARY EMBOLISM","source":"FDA FAERS","actionTaken":"553 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"473 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"453 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"360 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"349 reports"},{"date":"","signal":"THROMBOSIS","source":"FDA FAERS","actionTaken":"344 reports"}],"drugInteractions":[{"drug":"oral anticoagulants","severity":"","mechanism":"Androgens may increase sensitivity to oral anticoagulants","management":"Dosage of anticoagulant may require reduction to maintain satisfactory therapeutic hypoprothrombinemia","clinicalEffect":"Increased anticoagulant effect; risk of over-anticoagulation"},{"drug":"oxyphenbutazone","severity":"","mechanism":"Concurrent administration with androgens","management":"","clinicalEffect":"Elevated serum levels of oxyphenbutazone"},{"drug":"insulin","severity":"","mechanism":"Metabolic effects of androgens may decrease blood glucose","management":"Monitor blood glucose; insulin dosage adjustment may be necessary","clinicalEffect":"Decreased insulin requirements in diabetic patients"}],"commonSideEffects":[{"effect":"Fatigue","drugRate":"58.3%","organSystem":"General disorders","placeboRate":"","totalAtRisk":36,"totalAffected":21,"trialsReporting":1},{"effect":"Nausea","drugRate":"50.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":36,"totalAffected":18,"trialsReporting":1},{"effect":"Pain","drugRate":"36.1%","organSystem":"General disorders","placeboRate":"","totalAtRisk":36,"totalAffected":13,"trialsReporting":1},{"effect":"Constipation","drugRate":"22.2%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":36,"totalAffected":8,"trialsReporting":1},{"effect":"Anemia","drugRate":"19.4%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":36,"totalAffected":7,"trialsReporting":1},{"effect":"Anorexia","drugRate":"19.4%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":36,"totalAffected":7,"trialsReporting":1},{"effect":"Vomiting","drugRate":"16.7%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":36,"totalAffected":6,"trialsReporting":1},{"effect":"Dysgeusia","drugRate":"13.9%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":36,"totalAffected":5,"trialsReporting":1},{"effect":"Creatinine increase","drugRate":"11.1%","organSystem":"Renal and urinary disorders","placeboRate":"","totalAtRisk":36,"totalAffected":4,"trialsReporting":1},{"effect":"Diarrhea","drugRate":"11.1%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":36,"totalAffected":4,"trialsReporting":1},{"effect":"Cough","drugRate":"8.3%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":36,"totalAffected":3,"trialsReporting":1},{"effect":"Dizziness or Lightheadedness","drugRate":"8.3%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":36,"totalAffected":3,"trialsReporting":1},{"effect":"Nocturia","drugRate":"8.3%","organSystem":"Renal and urinary disorders","placeboRate":"","totalAtRisk":36,"totalAffected":3,"trialsReporting":1},{"effect":"Weight loss","drugRate":"8.3%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":36,"totalAffected":3,"trialsReporting":1},{"effect":"Abdominal pain","drugRate":"5.6%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":36,"totalAffected":2,"trialsReporting":1},{"effect":"Edema","drugRate":"5.6%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":36,"totalAffected":2,"trialsReporting":1},{"effect":"Hypercalcemia","drugRate":"5.6%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":36,"totalAffected":2,"trialsReporting":1},{"effect":"Insomnia","drugRate":"5.6%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":36,"totalAffected":2,"trialsReporting":1},{"effect":"Memory impairment","drugRate":"5.6%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":36,"totalAffected":2,"trialsReporting":1},{"effect":"Thromboembolic event","drugRate":"5.6%","organSystem":"Vascular disorders","placeboRate":"","totalAtRisk":36,"totalAffected":2,"trialsReporting":1},{"effect":"Urinary retention","drugRate":"5.6%","organSystem":"Renal and urinary disorders","placeboRate":"","totalAtRisk":36,"totalAffected":2,"trialsReporting":1}],"contraindications":["Known hypersensitivity to the drug","Males with carcinoma of the breast","Males with known or suspected carcinoma of the prostate gland","Women who are pregnant","Patients with serious cardiac, hepatic or renal disease"],"specialPopulations":{"Pregnancy":"The use of testosterone in women who are pregnant is contraindicated. Testosterone is teratogenic and may cause fetal harm. Testosterone is known to cause virilization of the female fetus when administered to pregnant women.","Geriatric use":"Geriatric patients treated with androgens may be at an increased risk of developing BPH and prostatic carcinoma.","Paediatric use":"Safety and effectiveness in pediatric patients below the age of 12 years have not been established."},"seriousAdverseEvents":[{"event":"Subdural hematoma","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"2.8%"},{"event":"Myocardial infarction","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"2.8%"},{"event":"Rib fracture","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"2.8%"},{"event":"Stroke","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"2.8%"},{"event":"Cord compression","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"2.8%"}]},"trials":[],"aliases":[],"company":"Azurity","patents":[{"applNo":"N216318","source":"FDA Orange Book","status":"Active","expires":"Mar 25, 2039","useCode":"","territory":"US","drugProduct":true,"patentNumber":"12138271","drugSubstance":false},{"applNo":"N216318","source":"FDA Orange Book","status":"Active","expires":"Mar 25, 2039","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11642355","drugSubstance":false},{"applNo":"N216318","source":"FDA Orange Book","status":"Active","expires":"Mar 25, 2039","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11311554","drugSubstance":false}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.3280/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$485","description":"TESTOSTERONE 1% (25 MG/2.5 G) PK","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Testosterone Cypionate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:33:27.188513+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:33:27.188405+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Testosterone Cypionate","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:33:36.504758+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"Haiku strategic summary","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T07:56:03.498725+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:33:33.319745+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:33:26.025558+00:00"},"pharmacokinetics":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:36:24.168794+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Testosterone Cypionate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:33:35.192386+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:33:23.977311+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:34:21.352559+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:33:23.977345+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:33:36.942198+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Androgen Receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:33:36.504700+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:56:03.498720+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201101/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:33:36.042549+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:36:24.339151+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:56:03.498716+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA207742","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:33:23.977348+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:55:59.082903+00:00"}},"allNames":["testosterone cypionate","testosterone cyclopentylpropionate"],"offLabel":[],"synonyms":["testosterone cypionate","testosterone cyclopentylpropionate"],"timeline":[{"date":"1978-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from WATSON LABS to Azurity"},{"date":"1978-06-23","type":"positive","source":"DrugCentral","milestone":"FDA approval (Watson Labs)"}],"aiSummary":"Testosterone cypionate is an intramuscular androgen replacement therapy indicated for male hypogonadism conditions. It has a half-life of approximately eight days with 98% plasma protein binding and hepatic metabolism. Contraindications include breast/prostate cancer, pregnancy, and serious cardiac, hepatic, or renal disease. Drug interactions with anticoagulants and insulin require dosage monitoring and adjustment.","brandName":"Testosterone Cypionate","ecosystem":[{"indication":"Deficiency of testosterone biosynthesis","otherDrugs":[{"name":"fluoxymesterone","slug":"fluoxymesterone","company":""},{"name":"methyltestosterone","slug":"methyltestosterone","company":"Valeant Pharm Intl"},{"name":"testosterone","slug":"testosterone","company":"Actient Pharms"},{"name":"testosterone enantate","slug":"testosterone-enantate","company":"Endo Pharms"}],"globalPrevalence":null},{"indication":"Delayed puberty","otherDrugs":[{"name":"fluoxymesterone","slug":"fluoxymesterone","company":""},{"name":"methyltestosterone","slug":"methyltestosterone","company":"Valeant Pharm Intl"},{"name":"testosterone","slug":"testosterone","company":"Actient Pharms"},{"name":"testosterone enantate","slug":"testosterone-enantate","company":"Endo Pharms"}],"globalPrevalence":null},{"indication":"Hormone receptor positive malignant neoplasm of breast","otherDrugs":[{"name":"abemaciclib","slug":"abemaciclib","company":"Eli Lilly And Co"},{"name":"anastrozole","slug":"anastrozole","company":"Astrazeneca"},{"name":"everolimus","slug":"everolimus","company":"Novartis"},{"name":"exemestane","slug":"exemestane","company":"Pharmacia And Upjohn"}],"globalPrevalence":null},{"indication":"Klinefelter's syndrome, XXY","otherDrugs":[{"name":"fluoxymesterone","slug":"fluoxymesterone","company":""},{"name":"testosterone","slug":"testosterone","company":"Actient Pharms"},{"name":"testosterone enantate","slug":"testosterone-enantate","company":"Endo Pharms"},{"name":"testosterone propionate","slug":"testosterone-propionate","company":"Watson Labs"}],"globalPrevalence":null},{"indication":"LHRH Deficiency","otherDrugs":[{"name":"fluoxymesterone","slug":"fluoxymesterone","company":""},{"name":"methyltestosterone","slug":"methyltestosterone","company":"Valeant Pharm Intl"},{"name":"testosterone","slug":"testosterone","company":"Actient Pharms"},{"name":"testosterone enantate","slug":"testosterone-enantate","company":"Endo Pharms"}],"globalPrevalence":null},{"indication":"Male hypogonadism","otherDrugs":[{"name":"fluoxymesterone","slug":"fluoxymesterone","company":""},{"name":"methyltestosterone","slug":"methyltestosterone","company":"Valeant Pharm Intl"},{"name":"testosterone","slug":"testosterone","company":"Actient Pharms"},{"name":"testosterone enantate","slug":"testosterone-enantate","company":"Endo Pharms"}],"globalPrevalence":null},{"indication":"Menopausal flushing","otherDrugs":[{"name":"bazedoxifene","slug":"bazedoxifene","company":"Wyeth Pharms Pfizer"},{"name":"conjugated estrogens","slug":"conjugated-estrogens","company":"Wyeth Pharms Inc"},{"name":"drospirenone","slug":"drospirenone","company":"Exeltis Usa Inc"},{"name":"estradiol","slug":"estradiol","company":"Bristol Myers Squibb"}],"globalPrevalence":null},{"indication":"Undescended testicle","otherDrugs":[{"name":"fluoxymesterone","slug":"fluoxymesterone","company":""},{"name":"testosterone","slug":"testosterone","company":"Actient Pharms"},{"name":"testosterone enantate","slug":"testosterone-enantate","company":"Endo Pharms"},{"name":"testosterone propionate","slug":"testosterone-propionate","company":"Watson Labs"}],"globalPrevalence":null}],"mechanism":{"target":"Androgen receptor","novelty":"Follow-on","targets":[{"gene":"AR","source":"DrugCentral","target":"Androgen receptor","protein":"Androgen receptor"}],"moaClass":"Androgen Receptor Agonists","modality":"Small Molecule","drugClass":"Androgen","explanation":"","oneSentence":"","technicalDetail":"Testosterone Cypionate is a synthetic androgen that binds to androgen receptors (AR) with high affinity, activating downstream signaling pathways that regulate gene expression and cellular function."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Testosterone_cypionate","title":"Testosterone cypionate","extract":"Testosterone cypionate, sold under the brand name Depo-Testosterone among others, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men, including hormone therapy for transgender men. It is given by injection into muscle or subcutaneously, once every one to four weeks, depending on clinical indication.","wiki_history":"==History==\nTestosterone cypionate was first synthesized in 1951 and was introduced for medical use in the United States the same year under the brand name Depo-Testosterone.","wiki_society_and_culture":"==Society and culture==\n\n===Generic names===\nTestosterone cypionate is the generic name of the drug and its .\n\n=== Brand names ===\n\nTestosterone cypionate is or has been marketed under a variety of brand names, including:\n\n* Andro Cyp\n* Andronaq LA\n* Andronate\n* Dep Andro\n* Dep Test\n* Deposteron\n* Depostomead\n* Depotest\n* Depo-Testosterone\n* Depovirin\n* Durandro\n* Duratest\n* Jectatest\n* Malogen CYP\n* Pertestis\n* Testa-C\n* Testadiate Depo\n* Testex Elmu Prolongatum\n* Testoject LA\n* Virilon\n\n===Availability===\n\n\nTestosterone cypionate is marketed in the United States."},"commercial":{"launchDate":"1978","_launchSource":"DrugCentral (FDA 1978-06-23, WATSON LABS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4454","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Testosterone%20Cypionate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Testosterone Cypionate","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Testosterone_cypionate","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T01:58:41.205965","_validation":{"fieldsValidated":6,"lastValidatedAt":"2026-04-20T08:36:25.295193+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"abiraterone acetate","drugSlug":"abiraterone-acetate","fdaApproval":"2011-04-28","patentExpiry":"May 20, 2034","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"apalutamide","drugSlug":"apalutamide","fdaApproval":"2018-02-14","patentExpiry":"Sep 23, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bicalutamide","drugSlug":"bicalutamide","fdaApproval":"1995-10-04","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"clascoterone","drugSlug":"clascoterone","fdaApproval":"2020-08-26","patentExpiry":"Nov 20, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"danazol","drugSlug":"danazol","fdaApproval":"1976-06-21","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"darolutamide","drugSlug":"darolutamide","fdaApproval":"2019-07-30","patentExpiry":"Oct 27, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dexamethasone","drugSlug":"dexamethasone","fdaApproval":"1958-10-30","patentExpiry":"Oct 7, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dexamethasone phosphate","drugSlug":"dexamethasone-phosphate","fdaApproval":"1959-09-02","relationship":"same-target"},{"drugName":"dorzolamide","drugSlug":"dorzolamide","fdaApproval":"1994-12-09","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"drospirenone","drugSlug":"drospirenone","fdaApproval":"2019-05-23","patentExpiry":"Jun 28, 2031","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"testosterone cypionate","indications":{"approved":[{"id":"depo-testosterone-primary-hypogonadism","name":"Primary Hypogonadism","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Males with primary hypogonadism","pivotalTrial":null,"restrictions":[],"patientPopulation":"Males with primary hypogonadism","diagnosticRequired":null,"brandNameForIndication":"Testosterone Cypionate"},{"id":"depo-testosterone-hypogonadotropic-hypogonadism","name":"Hypogonadotropic Hypogonadism","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Males with hypogonadotropic hypogonadism","pivotalTrial":null,"restrictions":[],"patientPopulation":"Males with hypogonadotropic hypogonadism","diagnosticRequired":null,"brandNameForIndication":"Testosterone Cypionate"}],"offLabel":[],"pipeline":[]},"currentOwner":"Azurity","drugCategory":"established","labelChanges":[],"relatedDrugs":[{"drugId":"abiraterone-acetate","brandName":"abiraterone acetate","genericName":"abiraterone acetate","approvalYear":"2011","relationship":"same-target"},{"drugId":"apalutamide","brandName":"apalutamide","genericName":"apalutamide","approvalYear":"2018","relationship":"same-target"},{"drugId":"bicalutamide","brandName":"bicalutamide","genericName":"bicalutamide","approvalYear":"1995","relationship":"same-target"},{"drugId":"clascoterone","brandName":"clascoterone","genericName":"clascoterone","approvalYear":"2020","relationship":"same-target"},{"drugId":"danazol","brandName":"danazol","genericName":"danazol","approvalYear":"1976","relationship":"same-target"},{"drugId":"darolutamide","brandName":"darolutamide","genericName":"darolutamide","approvalYear":"2019","relationship":"same-target"},{"drugId":"dexamethasone","brandName":"dexamethasone","genericName":"dexamethasone","approvalYear":"1958","relationship":"same-target"},{"drugId":"dexamethasone-phosphate","brandName":"dexamethasone phosphate","genericName":"dexamethasone phosphate","approvalYear":"1959","relationship":"same-target"},{"drugId":"dorzolamide","brandName":"dorzolamide","genericName":"dorzolamide","approvalYear":"1994","relationship":"same-target"},{"drugId":"drospirenone","brandName":"drospirenone","genericName":"drospirenone","approvalYear":"2019","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07481942","phase":"","title":"Body Composition Assessment in Transgender Population.","status":"COMPLETED","sponsor":"Celia Bañuls","startDate":"2017-01-01","conditions":["Transgender"],"enrollment":70,"completionDate":"2025-10-31"},{"nctId":"NCT07476001","phase":"PHASE2","title":"Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-03","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":12,"completionDate":"2027-09"},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":60,"completionDate":"2034-06-01"},{"nctId":"NCT07278362","phase":"PHASE4","title":"Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-05-31","conditions":["Prostate Cancer","Hypogonadism, Male"],"enrollment":35,"completionDate":"2032-05-31"},{"nctId":"NCT06305598","phase":"PHASE1","title":"Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-12-19","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":14,"completionDate":"2027-12-15"},{"nctId":"NCT04558866","phase":"PHASE2","title":"Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2021-06-09","conditions":["Prostate Cancer"],"enrollment":51,"completionDate":"2026-06"},{"nctId":"NCT04731376","phase":"PHASE1","title":"Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-01-25","conditions":["Hypogonadism","Malignant Urinary System Neoplasm","Urinary System Disorder","Urinary System Neoplasm"],"enrollment":56,"completionDate":"2026-12-31"},{"nctId":"NCT07092527","phase":"PHASE4","title":"Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-12-05","conditions":["Transgenderism","Reproductive Issues"],"enrollment":80,"completionDate":"2028-11-30"},{"nctId":"NCT06039371","phase":"PHASE2","title":"Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-05-21","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":69,"completionDate":"2027-12-31"},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":["Prostate Cancer"],"enrollment":50,"completionDate":"2029-11-30"},{"nctId":"NCT07328542","phase":"PHASE4","title":"Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men","status":"NOT_YET_RECRUITING","sponsor":"Azurity Pharmaceuticals","startDate":"2026-02","conditions":["Hypogonadism, Male"],"enrollment":144,"completionDate":"2027-08"},{"nctId":"NCT04895306","phase":"PHASE2","title":"Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-15","conditions":["Pain","Opioid Use","Androgen Deficiency","Back Pain"],"enrollment":40,"completionDate":"2026-06-30"},{"nctId":"NCT06100705","phase":"PHASE2","title":"Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-12-20","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":26,"completionDate":"2028-03"},{"nctId":"NCT03516812","phase":"PHASE2","title":"Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2018-08-29","conditions":["Castration-Resistant Prostate Carcinoma","Prostate Adenocarcinoma"],"enrollment":36,"completionDate":"2024-04-12"},{"nctId":"NCT03716739","phase":"PHASE2","title":"Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-03-19","conditions":["Prostate Cancer"],"enrollment":136,"completionDate":"2025-07-16"},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":50,"completionDate":"2031-08-30"},{"nctId":"NCT06450405","phase":"PHASE4","title":"Androgen Effects on the Reproductive Neuroendocrine Axis","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2025-02-26","conditions":["Transgenderism","Reproductive Issues"],"enrollment":2,"completionDate":"2025-03-03"},{"nctId":"NCT04363164","phase":"PHASE2","title":"Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-08-19","conditions":["Castration Resistant Metastatic Prostate Cancer"],"enrollment":150,"completionDate":"2027-07"},{"nctId":"NCT06111209","phase":"PHASE2","title":"The Anabolic Effect of Testosterone on Pelvic Floor Muscles","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-02-15","conditions":["Stress Urinary Incontinence","Menopause"],"enrollment":30,"completionDate":"2026-05-31"},{"nctId":"NCT04460872","phase":"PHASE2","title":"Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury","status":"RECRUITING","sponsor":"North Florida Foundation for Research and Education","startDate":"2021-01-31","conditions":["Spinal Cord Injury","Spinal Cord Injuries","Trauma, Nervous System","Wounds and Injury","Central Nervous System Diseases","Spinal Cord Diseases","Gonadal Disorders","Endocrine System Diseases","Hypogonadism","Genital Diseases, Male","Spinal Cord Trauma","Injuries, Spinal Cord","Walking, Difficulty","Gait Disorders, Neurologic","Locomotion Disorder, Neurologic","Wounds and Injuries","Nervous System Diseases","Testosterone Deficiency","Androgen Deficiency","Hormone Deficiency"],"enrollment":21,"completionDate":"2026-06-30"},{"nctId":"NCT05487794","phase":"NA","title":"Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men with Erythrocytosis","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2022-09-01","conditions":["Testosterone","Transsexualism","Hematologic Diseases"],"enrollment":46,"completionDate":"2024-12-17"},{"nctId":"NCT04321551","phase":"PHASE4","title":"Hormone Secretion in Transgender Males","status":"WITHDRAWN","sponsor":"University of California, San Diego","startDate":"2023-07-01","conditions":["Transgender","Healthy"],"enrollment":0,"completionDate":"2028-12-31"},{"nctId":"NCT06462482","phase":"PHASE4","title":"Peri-Operative Testosterone Administration in Primary Hip Arthroscopy","status":"NOT_YET_RECRUITING","sponsor":"American Hip Institute","startDate":"2025-01","conditions":["Femoro Acetabular Impingement"],"enrollment":60,"completionDate":"2026-12"},{"nctId":"NCT06608914","phase":"PHASE4","title":"Peri-Operative Testosterone Administration in Primary Total Hip Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"American Hip Institute","startDate":"2025-01","conditions":["Osteoarthritis, Hip"],"enrollment":60,"completionDate":"2026-12"},{"nctId":"NCT06592144","phase":"PHASE4","title":"TESTO-TRIAL: Use of Testosterone in Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Leticia Maria Defendi Barboza Marson","startDate":"2024-09-09","conditions":["Weaning Failure","Muscle Weakness","Mechanical Ventilation Complication","ICU Acquired Weakness","Mobility Limitation"],"enrollment":94,"completionDate":"2026-11-02"},{"nctId":"NCT03554317","phase":"PHASE2","title":"COMbination of Bipolar Androgen Therapy and Nivolumab","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-09-05","conditions":["Castration-resistant Prostate Cancer","Metastatic Prostate Cancer","Prostate Cancer"],"enrollment":45,"completionDate":"2023-01-06"},{"nctId":"NCT02995330","phase":"PHASE1","title":"Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-02-09","conditions":["Prostate Cancer"],"enrollment":3,"completionDate":"2021-06-16"},{"nctId":"NCT04551144","phase":"","title":"Effect of Transgender Therapy on Muscle, Fat and Tissue Receptors","status":"TERMINATED","sponsor":"St. Louis University","startDate":"2020-10-06","conditions":["Gender Incongruence","Transgenderism"],"enrollment":4,"completionDate":"2023-01-18"},{"nctId":"NCT04439799","phase":"PHASE4","title":"A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections","status":"COMPLETED","sponsor":"University of Miami","startDate":"2020-08-07","conditions":["Hypogonadism, Male"],"enrollment":81,"completionDate":"2023-02-09"},{"nctId":"NCT02248701","phase":"PHASE2","title":"Testosterone Plus Finasteride Treatment After Spinal Cord Injury","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2017-04-27","conditions":["Spinal Cord Injury","Spinal Cord Injuries","Trauma, Nervous System","Wounds and Injuries","Central Nervous System Diseases","Nervous System Diseases","Spinal Cord Diseases","Gonadal Disorders","Endocrine System Diseases","Hypogonadism","Genital Diseases, Male"],"enrollment":33,"completionDate":"2021-08-13"},{"nctId":"NCT04424654","phase":"PHASE2","title":"Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy","status":"COMPLETED","sponsor":"Hospital Sirio-Libanes","startDate":"2020-09-22","conditions":["Prostate Cancer"],"enrollment":20,"completionDate":"2022-07-01"},{"nctId":"NCT02090114","phase":"PHASE2","title":"RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-08-25","conditions":["Prostate Cancer"],"enrollment":112,"completionDate":"2021-11-11"},{"nctId":"NCT03325647","phase":"PHASE4","title":"TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-11-06","conditions":["Klinefelter Syndrome"],"enrollment":72,"completionDate":"2021-05-05"},{"nctId":"NCT04345666","phase":"PHASE2,PHASE3","title":"Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair","status":"WITHDRAWN","sponsor":"Orthopedic Institute, Sioux Falls, SD","startDate":"2021-08","conditions":["Rotator Cuff Tears"],"enrollment":0,"completionDate":"2023-01"},{"nctId":"NCT00853502","phase":"PHASE2","title":"The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2008-12","conditions":["Bone Metabolism"],"enrollment":0,"completionDate":"2016-10"},{"nctId":"NCT03792477","phase":"PHASE1","title":"A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-01-19","conditions":["Hypogonadism"],"enrollment":74,"completionDate":"2020-04-02"},{"nctId":"NCT02286921","phase":"PHASE2","title":"Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-01","conditions":["Castration Resistant Metastatic Prostate Cancer"],"enrollment":222,"completionDate":"2020-02-21"},{"nctId":"NCT04207684","phase":"PHASE1","title":"Generation of Biological Samples Positive to Testosterone for Anti-doping Control","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2020-02-04","conditions":["Healthy Volunteers"],"enrollment":4,"completionDate":"2020-02-26"},{"nctId":"NCT02408445","phase":"PHASE4","title":"Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-05-08","conditions":["Klinefelter Syndrome"],"enrollment":20,"completionDate":"2020-01-01"},{"nctId":"NCT02803073","phase":"PHASE2,PHASE3","title":"Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction","status":"WITHDRAWN","sponsor":"Texas Tech University Health Sciences Center","startDate":"2016-08","conditions":["Hypogonadism","Acute Myocardial Infarction: Rehabilitation Phase"],"enrollment":0,"completionDate":"2017-05"},{"nctId":"NCT03091348","phase":"PHASE4","title":"Subcutaneous vs. Intramuscular Testosterone","status":"COMPLETED","sponsor":"Men's Health Boston","startDate":"2017-08-29","conditions":["Testosterone Deficiency","Hypogonadism, Male"],"enrollment":4,"completionDate":"2018-01-02"},{"nctId":"NCT00179517","phase":"PHASE2","title":"Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2001-06","conditions":["Seizure Disorder","Hypogonadism","Erectile Dysfunction"],"enrollment":40,"completionDate":"2008-04"},{"nctId":"NCT01378299","phase":"PHASE1","title":"CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2011-10-01","conditions":["Hypogonadism"],"enrollment":105,"completionDate":"2017-11-07"},{"nctId":"NCT02081300","phase":"PHASE3","title":"Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2014-02","conditions":["Male Hypogonadism"],"enrollment":315,"completionDate":"2015-05"},{"nctId":"NCT03038919","phase":"PHASE2,PHASE3","title":"Role of Anabolic Steroids on Intensive Care Unit-Acquired Weakness","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2016-10","conditions":["Critical Illness Polyneuropathies"],"enrollment":30,"completionDate":"2018-01"},{"nctId":"NCT01750398","phase":"PHASE2","title":"Bipolar Androgen-based Therapy for Prostate Cancer (BAT)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-01","conditions":["Recurrent Prostate Cancer"],"enrollment":33,"completionDate":"2015-06"},{"nctId":"NCT00965341","phase":"PHASE3","title":"Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-09","conditions":["Advanced Cancer"],"enrollment":53,"completionDate":"2012-09"},{"nctId":"NCT02229617","phase":"PHASE1,PHASE2","title":"Subcutaneous Testosterone Project","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2015-07","conditions":["Gender Dysphoria"],"enrollment":14,"completionDate":"2016-05"},{"nctId":"NCT02222558","phase":"PHASE2","title":"Oral Testosterone for the Treatment of Hypogonadism in Males","status":"COMPLETED","sponsor":"TesoRx Pharma, LLC","startDate":"2014-09","conditions":["Hypogonadism"],"enrollment":25,"completionDate":"2015-05"},{"nctId":"NCT01084759","phase":"NA","title":"A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-03","conditions":["Prostate Cancer"],"enrollment":16,"completionDate":"2014-10"},{"nctId":"NCT01717768","phase":"PHASE2","title":"Oral Testosterone for the Treatment of Hypogonadism","status":"COMPLETED","sponsor":"TesoRx Pharma, LLC","startDate":"2012-10","conditions":["Hypogonadism"],"enrollment":130,"completionDate":"2014-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"TESTOSTERONE CYPIONATE"},{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"Testosterone Cypionate"},{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"Testosterone Cypionate"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"Depo-Testosterone"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"Testosterone Cypionate"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"testosterone cypionate"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"TESTOSTERONE"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000179263","MMSL":"2966","NDDF":"001245","UNII":"M0XW1UBI14","VUID":"4017483","CHEBI":"CHEBI:9463","VANDF":"4017483","INN_ID":"1900","RXNORM":"10379","UMLSCUI":"C0076181","chemblId":"CHEMBL1201101","ChEMBL_ID":"CHEMBL1201101","KEGG_DRUG":"D00957","DRUGBANK_ID":"DB13943","PDB_CHEM_ID":" TES","PUBCHEM_CID":"441404","SNOMEDCT_US":"109033004","MESH_DESCRIPTOR_UI":"D013739"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1978-","companyName":"Watson Labs","relationship":"Original Developer"},{"period":"present","companyName":"Azurity","relationship":"Current Owner"}],"pharmacokinetics":{"tmax":"","halfLife":"approximately eight days","clearance":"","excretion":"About 90 percent excreted in urine as glucuronic and sulfuric acid conjugates; about 6 percent excreted in feces mostly in unconjugated form","metabolism":"Inactivated primarily in the liver; metabolized to various 17-keto steroids through two different pathways; reduced to dihydrotestosterone in many tissues","proteinBinding":"98 percent bound to testosterone-estradiol binding globulin; approximately 2 percent free","bioavailability":"","volumeOfDistribution":""},"publicationCount":198,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"originalDeveloper":"Watson Labs","recentPublications":[{"date":"2026 Jan 5","pmid":"41503895","title":"Myocardial Infarction, Pulmonary Embolism, and Deep Vein Thrombosis Following Testosterone Cypionate Use: A Pharmacovigilance Study.","journal":"Current drug safety"},{"date":"2025","pmid":"41208903","title":"Accuracy of Anthropometric Equations in Estimating Body Fat Percentage in Transgender Men Undergoing Gender-Affirming Hormone Therapy.","journal":"International journal of exercise science"},{"date":"2025 Nov 3","pmid":"41150624","title":"Determinants of Pubertal Growth Spurt in Constitutional Delay of Growth and Puberty in Boys Treated With Testosterone.","journal":"Rhode Island medical journal (2013)"},{"date":"2025 Nov 2","pmid":"41052128","title":"Effect of 100 mg of testosterone cypionate in trans men with erythrocytosis: a randomized controlled pilot study.","journal":"The journal of sexual medicine"},{"date":"2025","pmid":"40895441","title":"Cross-sex hormone therapy in rats induces sex-specific adaptations of renal function and sodium transporters expression.","journal":"Frontiers in physiology"}],"companionDiagnostics":[],"genericManufacturers":14,"_genericFilersChecked":true,"genericManufacturerList":["Am Regent","Caplin One Labs","Cipla","Eugia Pharma","Hikma","Hikma Farmaceutica","Padagis Us","Pfizer","Rising","Sun Pharm Inds Ltd","Watson Labs","Watson Pharms Inc","Wilshire Pharms Inc","Xiromed"],"status":"approved","companyName":"Azurity","companyId":"azurity","modality":"Small molecule","firstApprovalDate":"1978","enrichmentLevel":5,"visitCount":11,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-06-19T00:00:00.000Z","mah":"PADAGIS US","brand_name_local":null,"application_number":"ANDA040530"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-06-16T00:00:00.000Z","mah":"AM REGENT","brand_name_local":null,"application_number":"ANDA207742"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-06-19T00:00:00.000Z","mah":"CIPLA","brand_name_local":null,"application_number":"ANDA210362"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-04-24T00:00:00.000Z","mah":"WILSHIRE PHARMS INC","brand_name_local":null,"application_number":"ANDA206368"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-06-02T00:00:00.000Z","mah":"AZURITY","brand_name_local":null,"application_number":"NDA216318"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"485.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"485.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"485.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"485.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"485.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":10,"withResults":2},"validation":{"fieldsValidated":6,"lastValidatedAt":"2026-04-20T08:36:25.295193+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}